Explore

Rapid Read Rapid Read
Japanese Fruit Sarunashi Shows Potential in Preventing Lung Cancer in Mice

Japanese Fruit Sarunashi Shows Potential in Preventing Lung Cancer in Mice

Researchers at Okayama University have identified a small Japanese fruit, Sarunashi (Actinidia arguta), also known as the kiwiberry, as a potential agent in preventing lung cancer. In a study published in the journal Genes and Environment, the fruit's juice was found to reduce lung tumor formation in mice exposed to NNK, a carcinogen related to tobacco. The juice also decreased the number of tumor nodules in the lungs, and its compound isoquercetin demonstrated protective effects. The study suggests that Sarunashi juice may interfere with the initiation and growth of cancer by reducing DNA damage and supporting DNA repair mechanisms. While these findings are promising, clinical trials are necessary to confirm the fruit's efficacy in humans.
Trendline Trendline
AvenCell Therapeutics Initiates Phase I Study of Novel CAR-T Therapy for B-Cell Malignancies

AvenCell Therapeutics Initiates Phase I Study of Novel CAR-T Therapy for B-Cell Malignancies

AvenCell Therapeutics Initiates Phase I Study of Novel CAR-T Therapy for B-Cell Malignancies
Rapid Read Rapid Read
University of Colorado Anschutz Gains FDA Clearance for CAR T-Cell Therapy

University of Colorado Anschutz Gains FDA Clearance for CAR T-Cell Therapy

The University of Colorado Anschutz Gates Institute has achieved a significant milestone by receiving FDA clearance for a new CAR T-cell therapy developed entirely on its campus. This therapy targets the CD64 protein on leukemia cells and is designed for patients with relapsed or refractory acute myeloid leukemia (AML). The clearance marks the first time a CAR T-cell therapy developed on a university campus has been authorized for clinical testing in the U.S. The Phase 1 clinical trial will begin in June 2026, focusing on evaluating the safety and optimal dosing of the therapy in adults with AML. This development is the result of years of research and collaboration among scientists, clinicians, and regulatory teams at the Gates Institute.
Trendline Trendline
Wugen Selected for FDA Pilot Program to Advance Manufacturing of Soficabtagene Geleucel

Wugen Selected for FDA Pilot Program to Advance Manufacturing of Soficabtagene Geleucel

Wugen Selected for FDA Pilot Program to Advance Manufacturing of Soficabtagene Geleucel
Rapid Read Rapid Read
Innovative Therapy Shows Promise in Halting Prostate Cancer Spread to Bone

Innovative Therapy Shows Promise in Halting Prostate Cancer Spread to Bone

Researchers at the VCU Massey Comprehensive Cancer Center have developed a new targeted therapy that effectively prevents prostate cancer from spreading to the bones. The therapy, involving a small molecule inhibitor called IVMT-Rx-4, has shown promising results in preclinical models by blocking the function of a gene known as MDA-9/syntenin, which is responsible for tumor growth and metastasis. This innovative approach not only halts the progression of prostate cancer to an advanced stage but also enhances the efficacy of existing chemotherapy treatments. The findings, published in Pharmacological Research, suggest a potential paradigm shift in treating metastatic prostate cancer.
Trendline Trendline
Delcath Systems to Showcase Liver Cancer Treatment at Radiology Meeting

Delcath Systems to Showcase Liver Cancer Treatment at Radiology Meeting

Delcath Systems to Showcase Liver Cancer Treatment at Radiology Meeting
Rapid Read Rapid Read
Feinstein Institutes Awards 2026 Ross Prize to Drs. Michel Sadelain and Carl H. June for CAR T-cell Therapy Innovations

Feinstein Institutes Awards 2026 Ross Prize to Drs. Michel Sadelain and Carl H. June for CAR T-cell Therapy Innovations

The Feinstein Institutes for Medical Research has announced that Dr. Carl H. June from the University of Pennsylvania and Dr. Michel Sadelain from Columbia University will receive the 13th annual Ross Prize in Molecular Medicine. The award ceremony is scheduled for June 11 in New York City, in collaboration with The New York Academy of Sciences. The award recognizes their pioneering work in developing CAR T-cell therapy, a groundbreaking treatment for cancer. This therapy involves genetically engineering a patient's T cells to target and destroy cancer cells, offering new hope for patients with refractory leukemias and other cancers. The Ross Prize, established in 2013, includes a $50,000 award and is presented to researchers whose work has the potential to transform disease treatment.
Trendline Trendline
Wugen's Soficabtagene Geleucel Selected for FDA Pilot Program to Enhance Manufacturing Readiness

Wugen's Soficabtagene Geleucel Selected for FDA Pilot Program to Enhance Manufacturing Readiness

Wugen's Soficabtagene Geleucel Selected for FDA Pilot Program to Enhance Manufacturing Readiness
Rapid Read Rapid Read
Novel Cancer Treatment Shows Promise in Mice, Combining HIF Inhibitors with Immunotherapy

Novel Cancer Treatment Shows Promise in Mice, Combining HIF Inhibitors with Immunotherapy

Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed new small molecule drugs that inhibit hypoxia-inducible factors 1 and 2 (HIF-1/2), which are key regulators of cancer progression. These drugs, when combined with immunotherapy, have shown the ability to completely eliminate various types of tumors in mice, including breast, colorectal, melanoma, and prostate cancers. The study suggests that these drugs could potentially be used to treat a wide range of cancers in humans by overcoming resistance to immune checkpoint blockade therapy.
Reuters Reuters
Trading Day: Oil Strait back up again

Trading Day: Oil Strait back up again

By Jamie McGeever ORLANDO, Florida, April 2 (Reuters) - World markets reeled on Thursday, with stocks mostly lower and U.S. oil soaring 11% after President Donald Trump indicated there will be no let-up in the war on Iran, meaning the Strait of Hormuz won't be opening up soon, as traders had hoped.
Trendline Trendline
Zai Lab and Amgen Collaborate on Novel Lung Cancer Treatment

Zai Lab and Amgen Collaborate on Novel Lung Cancer Treatment

Zai Lab and Amgen Collaborate on Novel Lung Cancer Treatment
Trendline Trendline
Zai Lab and Amgen Collaborate on Clinical Trial for Lung Cancer Treatment

Zai Lab and Amgen Collaborate on Clinical Trial for Lung Cancer Treatment

Zai Lab and Amgen Collaborate on Clinical Trial for Lung Cancer Treatment